Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Samih Darwazah

Hikma Pharmaceuticals PLC

AFT Pharmaceuticals Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. It offers products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, nail care, oral care, pain management, skin care, and supplements, as well as other products. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.

AFT Pharmaceuticals Limited

STERISYS is involved in the development and provision of automated handling systems and sterilization plants for the medical technology and pharmaceutical industries. The company focuses on engineering and constructing turnkey solutions for ethylene oxide sterilization.

STERISYS

For 45 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 760* high-quality generic, speciality and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 8 R&D centres and c9,100 employees worldwide. 

*As of February 2024

Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668

For all product information and enquiries, please contact us at PV@hikma.com 

Hikma Pharmaceuticals

Discover our exceptional track record at Hikma CMO. When you partner with us to produce your medicines, you’re accessing the same state-of-the-art 1,000,000 Sq. Ft. facility on 80 acres that the FDA has repeatedly used as a training site for qualifying new inspectors within their organization. With zero critical FDA observations for two decades, and best-in-class TRIR safety performance, you can lean on us for all your CMO needs. 
Meet Hikma’s CMO team at Interphex NYC April 16-18th at Booth #1154
#HikmaUS #HikmaCMO #Interphex2024


Aligned with our commitment to inspiring future pioneers, #Hikma #Portugal welcomed students from Alto dos Moinhos school, to our manufacturing plant in Sintra. The immersive tour bridged classroom learning, with real-world pharmaceutical operations, empowering the next generation through experiences that bring science to life. 

#FutureLeaders #YouthEmpowerment #PharmaCareers #STEMEducation 

#Hikma beim Prospitalia Kongress 2024 in Frankfurt 
Der Prospitalia Kongress findet vom 15. bis 16. April 2024 im Kap Europa in Frankfurt statt.  

Leopold Lindauer und Kristina Stumpf freuen sich auf Ihren Besuch und spannende Gespräche an unserem Stand Nr. E1.14. 

Hikma beliefert Apotheken und Krankenhäuser mit generischen injizierbaren Produkten, die in unseren sechs Produktionsstätten für injizierbare Arzneimittel in den USA, Europa und MENA hergestellt werden.  

#BetterHealth #WithinReach #EveryDay

On #WorldHealthDay, #Hikma is proud to champion equitable access to high-quality, affordable medicines for all. We take pride in the important role we play in manufacturing and providing affordable, high-quality medicines to treat a growing number of illnesses and conditions. Our customers, healthcare professionals and patients, look to us to meet their evolving needs and ensure reliable access to essential medicines. 

https://lnkd.in/eG5VmEEZ  

#WorldHealthDay #WHO #BetterHealthForAll #AccessToMedicine #MyHealthMyRight 

Hikma CMO delivers at the speed you demand, and we’re laser-focused on delivering agility, reliability and scalability. In under 24 months, our highly trained #Columbus, Ohio team recently brought to market a critical life-saving device using our effective, robust, and rapid-tech transfer process. Our proven drug technology capabilities can manufacture a broad range of dosage forms, with high-containment operations (HCO), nasal, liquids, bottle, blister, and bulk packaging options. 
Meet our team at Interphex NYC April 16-18th at Booth #1154
#HikmaUS #HikmaCMO #Interphex2024


Today, we proudly celebrate Tareq Darwazeh, our Chief Operating Officer for the #MENA region at #Hikma, recognised as a 2024 Young Global Leader by the World Economic Forum.

This underscores Tareq's #visionaryleadership, driving #innovation and advancement in the MENA pharmaceutical industry, and highlights his commitment to forging positive change in our communities for a more #inclusive and #sustainable world. 

Tareq joins outstanding young pioneers, representing the best of their generation globally. 

#WEF #YGL #YGL24 

Metric
Company Name	Hikma Pharmaceuticals PLC	AFT Pharmaceuticals Limited	STERISYS
Symbol	HIK	AFT
MSH ID	COM:HIKMA	COM:AFTPHARM	EU:STERISYS
Market	STOCKS	STOCKS	PRIVATE
Sector	Healthcare	Healthcare	Healthcare & Health Services
Industry	Drug Manufacturers - Specialty & Generic	Drug Manufacturers - Specialty & Generic	Medical Devices
Country	GB	NZ	BE
Stage
Employee Count	9.10K	110
Website	hikma.com	aftpharm.com	sterisys.eu
LinkedIn	hikma-pharmaceuticals
Founders

Metric
Market Cap	51.46M	180.44M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	2.88B	113.99M
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.39B	51.49M
EBITDA	871M	15.00M
Operating Income	367M	13.83M
Net Income	190M	9.11M
EPS	0.86	0.09
Diluted EPS	0.85	0.09
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.50	0.46
Operating Profit Margin	0.24	0.12
EBITDA Margin	0.30	0.13
Net Profit Margin	0.09	0.08
Return on Equity	0.13	0.30
Return on Assets	0.06	0.14
Return on Capital Employed	0.21	0.30

COM:HIKMA

Hikma Pharmaceuticals

Last Close

1,950.00

25/11 09:22

Market Cap

40.38M

Beta: -

Volume Today

39.31K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	57.06	36.81
P/B Ratio	2.49	5.35
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.00	1.46
EV Multiple	6.03	11.51

Metric
Days Sales Outstanding	287.13	92.80
Days Payables Outstanding	288.23	96.79
Days Inventory Outstanding	236.69	141.07
Operating Cycle	354.84	204.75
Cash Conversion Cycle	205.25	109.61
Asset Turnover	0.62	1.77

Metric
Operating Cash Flow	608M	14.90M
Free Cash Flow	404M	9.35M
Cash Flow to Debt	0.51	1.38
Operating Cash Flow/Sales	0.21	0.14
Free Cash Flow Yield	0.03	-0.02

Metric
Cash & Equivalents	205M	7.02M
Accounts Receivable		1.46M
Inventory	891M	28.62M
Goodwill	388M
Debt to Capitalization	0.36	0.34
Debt to Assets	0.28	0.26
Current Ratio	1.79	2.38
Quick Ratio	0.98	1.23

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01
R&D to Revenue	0.06	0.04
SG&A to Revenue	0.20	0.07